(30) discovered that FoxM1, along with an increase in the number of Foxp3+Treg, increased significantly in gastric cancer tissues, that overexpression of FoxM1 and Foxp3+Treg favored GC infiltration and invasion, and that inhibition of the regulatory pathways of FoxM1 and Foxp3 could block GC proliferation, implying that the combination of FoxM1 and Foxp3+Treg could be used as a biomarker for diagnosis and prognostic survival of clinical gastric cancer patients. The gene discussed is FOXP3; the disease is gastric cancer.